Planta CBD gummies are an over-the-counter hemp-derived CBD product not regulated by the Massachusetts Cannabis Control Commission, meaning their potency, purity, and labeling accuracy are not independently verified to the same standard as dispensary products. CBD interacts with CB1 and CB2 receptors and 5-HT1A serotonergic pathways, offering genuine therapeutic potential, but patients deserve physician-guided dosing and third-party verified formulations. Massachusetts medical cannabis patients can access rigorously tested, high-potency CBD products at dispensaries tax-free, with clinical oversight that OTC gummies simply cannot provide.
| Audience | Massachusetts Patients, Caregivers & Clinicians |
| Primary Topic | CBD Gummies Pharmacology, Safety, and Massachusetts Regulatory Context |
| Legal Authority | Massachusetts Cannabis Control Commission Regulations (935 CMR 501) |
What Patients Should Know About Planta CBD Gummies (2026 Doctor's Guide)
Planta CBD gummies are widely marketed online and in Massachusetts retail stores, but what patients rarely hear is how dramatically the quality, dosing accuracy, and regulatory oversight differ from dispensary-grade CBD. Understanding those distinctions-grounded in endocannabinoid biology and Massachusetts law-can meaningfully change your therapeutic outcomes.
- How Planta CBD gummies differ pharmacologically and regulatorily from Massachusetts dispensary-grade CBD products in 2026
- Why hemp-derived OTC CBD products are not subject to CCC batch-testing and labeling accuracy requirements under 935 CMR 501
- How CBD engages CB1, CB2, and 5-HT1A receptors to modulate anxiety, pain, and inflammation without the biphasic THC risk
- How Massachusetts medical cannabis patients save 17-20% in taxes and access physician-verified, high-potency CBD formulations unavailable OTC
- Practical steps to transition from unverified OTC CBD gummies to a medically supervised, dispensary-sourced CBD protocol
- Planta CBD gummies are unregulated OTC hemp products with no CCC-mandated batch testing or potency verification in Massachusetts
- Massachusetts medical cannabis law (M.G.L. c. 94I, 935 CMR 501) provides access to rigorously tested, physician-supervised CBD formulations
- CBD’s therapeutic action via CB1, CB2, and 5-HT1A pathways is real, but dose accuracy in OTC gummies is frequently unreliable
- Medical cannabis patients access dispensary CBD tax-free, saving 17-20%, with clinical guidance OTC products cannot offer
| Target Question | What Patients Should Know About Planta CBD Gummies (2026 Doctor's Guide) |
| Massachusetts Legal Basis | M.G.L. c. 94I & 935 CMR 501.000 |
| Qualifying Standard | Statutory 'Debilitating Medical Condition' determined by certifying physician; OTC CBD products fall outside CCC jurisdiction |
| Clinical Pharmacology | CBD modulates CB1/CB2 endocannabinoid receptors and 5-HT1A serotonergic pathways; no significant psychoactive biphasic risk at therapeutic doses |
| Tax Exemption Benefit | 100% exempt from Massachusetts state and local cannabis excise taxes (17-20% savings) for registered medical patients at dispensaries |
| Possession Limit | 60-day rolling supply of up to 10 ounces of cannabis flower or equivalent for registered Massachusetts medical patients |
| Certification Method | Physician clinical evaluation followed by immediate online MassCIP portal access; OTC CBD requires no certification but offers no clinical oversight |
Millions of Americans-including a rapidly growing number of Massachusetts residents-are reaching for CBD gummies as a first-line response to anxiety, sleep disruption, chronic pain, and inflammation. Planta is one of dozens of brands flooding this market, and patients deserve an honest clinical appraisal of what they are actually buying: a hemp-derived product manufactured outside the Massachusetts Cannabis Control Commission’s rigorous testing and labeling framework. The stakes are not trivial. Independent laboratory analyses of commercial CBD gummies have repeatedly found significant discrepancies between labeled and actual CBD content-sometimes delivering a fraction of the advertised dose, occasionally containing detectable THC levels that could surprise a patient or trigger a workplace drug screen. For Massachusetts patients who qualify for medical cannabis certification, the comparison is stark: dispensary CBD products are batch-tested, physician-supervised, and purchased tax-free. Understanding that distinction in 2026 is not a regulatory technicality-it is a genuine patient safety and therapeutic efficacy issue.
Planta CBD gummies may deliver some CBD-related benefit for mild symptoms, but patients relying on them for meaningful therapeutic outcomes are working without a safety net. The product is not batch-tested under Massachusetts CCC standards, the dose printed on the label may not reflect what is in the gummy, and there is no physician in the loop to catch drug interactions, adjust dosing, or flag contraindications. For Massachusetts patients managing anxiety, chronic pain, insomnia, or inflammatory conditions, the medically supervised dispensary pathway is categorically superior. You get verified potency, physician guidance, a 17-20% tax exemption, and access to formulations-including high-CBD tinctures, capsules, and balanced ratios-that simply do not exist in the OTC market. If Planta gummies are your current entry point into CBD, I respect that. But let’s make sure you are getting what you think you are getting, at a dose that actually works.
Planta CBD gummies are a commercially marketed hemp-derived cannabidiol product sold online and in retail stores across Massachusetts. Because they are derived from hemp (defined federally as Cannabis sativa with less than 0.3% THC by dry weight), they fall under the jurisdiction of the FDA and the Massachusetts Department of Agricultural Resources-not the Cannabis Control Commission. This means they are not subject to the CCC’s mandatory batch-testing protocols, seed-to-sale tracking requirements, or the strict labeling accuracy standards codified in 935 CMR 501.105.
In practical terms, this regulatory gap matters enormously. A 2020 study published in JAMA Network Open found that nearly 70% of commercially available CBD products were mislabeled-some containing significantly less CBD than advertised, others containing more THC than disclosed. While Planta may publish its own certificates of analysis, patients should understand that OTC COAs are typically commissioned by the manufacturer rather than mandated by an independent state regulator. That is a fundamentally different accountability structure than what Massachusetts dispensaries operate under.
None of this means Planta gummies are inherently dangerous or fraudulent. It means patients are navigating a less-regulated landscape and should approach OTC CBD with calibrated expectations, healthy skepticism about label claims, and ideally a conversation with a clinician before relying on any CBD product for a meaningful health condition.
CBD’s therapeutic profile is genuinely compelling, and the biology behind it is increasingly well-characterized. Unlike THC, CBD has low direct affinity for CB1 receptors-the receptor responsible for psychoactive effects-but it modulates the endocannabinoid system through several indirect mechanisms, including inhibition of fatty acid amide hydrolase (FAAH), the enzyme that breaks down anandamide, the body’s endogenous ‘bliss molecule.’ By slowing anandamide degradation, CBD effectively raises endocannabinoid tone without triggering the intoxicating CB1 agonism associated with THC. Simultaneously, CBD acts as a positive allosteric modulator at 5-HT1A serotonin receptors-the same receptor targeted by buspirone and partially by SSRIs-which helps explain its anxiolytic and antidepressant-adjacent effects observed in clinical studies. CBD also engages TRPV1 channels (relevant to pain and inflammation), GPR55 receptors, and has demonstrated anti-inflammatory activity via CB2 receptor modulation in peripheral immune tissue. For patients with anxiety, chronic pain, or inflammatory conditions, this multi-receptor pharmacology offers a genuinely broad therapeutic footprint-provided the dose is accurate and consistent, which is precisely where OTC gummies frequently fall short.
The most important clinical distinction between Planta gummies and dispensary CBD is not brand prestige-it is dose reliability. Therapeutic CBD dosing for anxiety typically ranges from 15 mg to 50 mg per dose in clinical literature, with some studies using 300 mg for acute social anxiety. If a gummy labeled ’25 mg CBD’ actually contains 12 mg or 38 mg, the patient’s ability to titrate effectively is severely compromised. Massachusetts dispensaries operating under 935 CMR 501 are required to test every batch for potency, pesticides, heavy metals, residual solvents, and microbial contaminants-and those results must be available to patients at point of sale.
Dispensary CBD products also offer formulation diversity that the OTC market cannot match. Medical patients in Massachusetts can access full-spectrum tinctures with precise CBD:THC ratios (such as 20:1 or 30:1), high-CBD capsules with consistent bioavailability, and sublingual strips that bypass first-pass hepatic metabolism for faster onset. Planta gummies, like most OTC edibles, are subject to the same variable gastrointestinal absorption that makes oral CBD notoriously unpredictable-with bioavailability estimates ranging from 6% to 19% depending on fed versus fasted state.
Terpene co-administration is another dimension entirely absent from most OTC CBD products. Dispensary-grade full-spectrum CBD preparations retain linalool (anxiolytic, found in lavender), myrcene (sedating, muscle-relaxing), and beta-caryophyllene (CB2 agonist, anti-inflammatory)-compounds that contribute meaningfully to the entourage effect. Planta gummies, like most commercial hemp extracts, are often CBD isolate or broad-spectrum products with terpene profiles that are either stripped or artificially reintroduced without the same clinical intentionality.
As of 2026, the Massachusetts Cannabis Control Commission’s regulatory authority under 935 CMR 501.000 applies exclusively to licensed cannabis operators-cultivators, manufacturers, retailers, and delivery licensees. Hemp-derived CBD products like Planta gummies are not within the CCC’s jurisdiction. They are governed instead by a patchwork of FDA guidance (which remains incomplete for ingestible CBD as of 2026, despite years of anticipated rulemaking), Massachusetts Department of Agricultural Resources hemp regulations, and general FTC truth-in-advertising standards. This means no mandatory state-level potency testing, no seed-to-sale tracking, and no dispensary-equivalent consumer protections.
Massachusetts medical cannabis patients registered through MassCIP, by contrast, operate within a fully defined statutory framework. Under M.G.L. c. 94I, registered patients may possess up to a 60-day supply of 10 ounces of cannabis or cannabis equivalent, purchase from any licensed medical dispensary statewide, and receive a 100% exemption from the state’s 10.75% cannabis excise tax plus applicable local taxes-a combined savings of 17-20% per transaction. For a patient spending $150 per month on CBD products, that exemption alone saves $25-$30 monthly, or $300-$360 annually. The certification process itself is straightforward: a telehealth consultation with a registered certifying physician, electronic submission to the CCC, and same-day access via the MassCIP temporary digital certificate.
CBD is generally well-tolerated, but ‘generally well-tolerated’ is not the same as ‘universally safe at any dose from any source.’ At higher doses, CBD can cause transient fatigue, diarrhea, and appetite changes. More clinically significant is CBD’s inhibition of cytochrome P450 enzymes-particularly CYP3A4 and CYP2C19-which metabolize a wide range of medications including warfarin, clobazam, certain SSRIs, and immunosuppressants. Patients on any of these medications who begin taking CBD gummies without physician oversight are running an unmonitored drug-drug interaction experiment.
For OTC products specifically, the additional concern is undisclosed THC content. Even trace amounts of THC in a product consumed daily can accumulate in fatty tissue and produce a positive urine drug screen-a real-world consequence for patients in safety-sensitive employment, those on probation, or those subject to workplace drug testing. Dispensary products carry verified THC content on every label; OTC gummies do not always offer the same assurance. Starting with a low dose, reviewing any available third-party COA, and disclosing CBD use to your prescribing physicians are the minimum harm-reduction steps any patient should take before relying on a commercial CBD product.
For patients managing complex diagnoses, severe chronic pain, psychiatric medication tapers, or high-stakes executive privacy, Dr. Caplan provides high-touch private physician advisory and medical quarterbacking beyond standard certification.
The clinical evidence base for CBD as a therapeutic agent has matured substantially by 2026. The FDA approval of Epidiolex (pharmaceutical-grade CBD) for Dravet syndrome and Lennox-Gastaut syndrome established proof-of-concept for CBD’s anticonvulsant and neurological efficacy at the highest regulatory standard. For anxiety, a landmark 2019 retrospective study in The Permanente Journal (Shannon et al.) found that 79% of patients reported decreased anxiety scores within the first month of CBD use. A 2020 randomized controlled trial in the New Zealand Journal of Psychiatry demonstrated significant reductions in anxiety, depression, and sleep disturbance with CBD. Preclinical and human neuroimaging studies have consistently shown CBD’s attenuation of amygdala hyperreactivity-the neurobiological signature of anxiety disorders-via 5-HT1A modulation. The evidence is not yet at the level of large Phase III RCTs for most anxiety subtypes, but the mechanistic plausibility, preclinical consistency, and accumulating clinical data collectively support CBD as a legitimate therapeutic tool when properly dosed and sourced.
Legitimate skepticism is warranted on several fronts. First, the commercial CBD market-including brands like Planta-is saturated with marketing language that dramatically outpaces the evidence. Claims of CBD ‘curing’ anxiety, inflammation, or chronic pain are not supported by current clinical data and in many cases violate FDA guidelines on disease claims for dietary supplements. Second, the placebo effect in anxiety treatment is robust and well-documented; patients who believe they are taking an effective anxiolytic will often report improvement regardless of the active ingredient. Third, the bioavailability of oral CBD gummies is genuinely poor and highly variable, meaning a patient may be spending significant money for inconsistent therapeutic exposure. Clinicians should also note that industry-funded studies on CBD products consistently show more favorable outcomes than independent research-a pattern that warrants scrutiny when evaluating brand-specific claims.
Purchasing Planta CBD gummies-or any CBD product-does not constitute medical treatment, does not replace a clinical evaluation for anxiety, depression, chronic pain, or any other condition, and does not provide the legal protections afforded to Massachusetts registered medical cannabis patients. A CBD gummy cannot substitute for emergency psychiatric care, crisis intervention, or evidence-based pharmacotherapy for severe mental health conditions. Medical cannabis certification is not a guarantee of symptom resolution; it is a gateway to a supervised, adjustable therapeutic tool within a broader treatment plan. Patients should not discontinue prescribed medications in favor of CBD without explicit physician guidance, and the presence of a ‘natural’ label on any product does not imply freedom from drug interactions, side effects, or quality concerns.
CBD gummies occupy a fascinating and somewhat awkward position in modern integrative medicine. They represent the consumer-facing tip of a genuinely promising pharmacological iceberg-a molecule with real receptor-level activity, a growing evidence base, and an FDA-approved pharmaceutical form-yet they are sold in gas stations and grocery stores with the same regulatory rigor applied to vitamin C chews. For clinicians practicing integrative medicine in 2026, the challenge is neither to dismiss CBD as snake oil nor to uncritically endorse every commercial formulation. The honest clinical position is that CBD can be a valuable therapeutic adjunct for the right patient, at the right dose, from a verified source, within a supervised treatment framework.
The self-medication dynamic is particularly important to acknowledge. Many patients who reach for Planta gummies are doing so because they have found conventional medicine inadequate, inaccessible, or too side-effect-laden for their needs. That impulse deserves respect, not dismissal. But self-medication with unverified OTC products-without disclosure to treating physicians, without dose titration guidance, and without monitoring for drug interactions-carries real risks that a brief clinical consultation could substantially mitigate. The goal is not to gatekeep CBD but to ensure patients get the most out of it safely.
Sleep hygiene, cognitive behavioral therapy, regular aerobic exercise, dietary anti-inflammatory strategies, and stress reduction practices like mindfulness-based stress reduction (MBSR) all have robust evidence bases for anxiety and chronic pain-conditions for which patients frequently seek CBD. The most effective clinical outcomes I observe at CED Clinic come from patients who integrate cannabis or CBD into a broader lifestyle and therapeutic framework rather than treating it as a standalone solution. CBD can lower the floor of baseline anxiety enough to make therapy more accessible, sleep more restorative, and exercise more tolerable-but it works best as part of a system, not as a replacement for one.
I see patients every week who come to me after months or years of buying CBD gummies from Amazon, CVS, or a wellness boutique-spending real money, experiencing inconsistent results, and genuinely unsure whether CBD is helping them or not. The honest answer is often: it might be helping, but you have no way to know, because you do not know what dose you are actually getting, whether the product contains what the label says, or whether it is interacting with anything else you are taking. That uncertainty is not a minor inconvenience-it is a fundamental obstacle to therapeutic progress.
What I try to offer every patient is clarity. When we sit down together, we review your full medication list, your symptom history, your goals, and your lifestyle. We talk about what the evidence actually supports for your specific situation-not what a brand’s marketing team wants you to believe. And when we design a CBD or cannabis protocol together, we start with verified products, documented doses, and a clear titration plan. That is not more complicated than buying gummies online. It is just more effective.
If you are currently using Planta gummies and finding some benefit, I am genuinely glad. But I want you to know that there is a more reliable, more cost-effective, and more clinically supported path available to you in Massachusetts right now. The medical cannabis system here is one of the most patient-friendly in the country, and the tax exemption alone often covers the cost of a consultation within the first few months. You deserve to know what you are taking, why it works, and how to adjust it when it stops working as well as it once did. That is what physician-guided cannabis medicine looks like in 2026.
If you are a Massachusetts patient considering or currently using Planta CBD gummies, the most important thing you can do is bring that use into a clinical conversation. CBD is a real medicine with real pharmacology, real drug interactions, and real dose-response relationships-and you deserve the same quality of oversight for your CBD protocol that you would expect for any other therapeutic intervention. The Massachusetts medical cannabis system in 2026 offers a straightforward, affordable, and legally protective pathway to verified CBD products with physician guidance. OTC gummies may be your starting point; they do not have to be your ceiling.
Examining Planta CBD Gummies and OTC CBD Through Eight Critical Lenses
Patients, clinicians, regulators, skeptics, and caregivers each evaluate commercial CBD products differently. These eight perspectives explore the evidence, the regulations, and the real-world practicalities from every angle.
Patient Takeaway
You have every right to buy CBD gummies at a retail store in Massachusetts-that is entirely legal and your choice to make. But if you are spending $40-$80 a month on OTC CBD for a real health condition, you should know that Massachusetts medical cannabis patients can access rigorously tested, physician-supervised CBD products at dispensaries while saving 17-20% in taxes. The product you get at a dispensary has been batch-tested by a state-licensed laboratory. The dose on the label reflects what is actually in the product. And you have a physician in your corner to help you adjust when things are not working. That is a meaningfully different experience than hoping a gummy from a wellness website delivers what it promises.
Clinician's Perspective
From a clinical standpoint, the primary concern with patients self-medicating with OTC CBD products is not the CBD itself-it is the absence of a structured therapeutic framework. Without a baseline assessment, a documented titration plan, and monitoring for drug-drug interactions via CYP450 pathways, clinicians have no meaningful way to evaluate whether CBD is contributing to a patient’s improvement or simply riding alongside a natural symptom fluctuation.
The CYP3A4 and CYP2C19 inhibition profile of CBD is clinically significant and frequently underappreciated. Patients on warfarin, clobazam, certain statins, or immunosuppressants who begin daily CBD gummies without disclosure are creating an unmonitored pharmacokinetic variable. A single clinical conversation can identify these risks before they become adverse events.
Collaborating with a patient’s primary care physician or psychiatrist when initiating a CBD protocol is not just good practice-it is essential for patients managing complex comorbidities. I routinely send clinical notes to referring providers documenting the rationale, formulation, and dosing strategy for every patient I certify, ensuring continuity of care across the treatment team.
A Skeptical Read
The CBD gummy market-Planta included-is built substantially on consumer enthusiasm that has outpaced the clinical evidence. The placebo effect in anxiety and pain conditions is robust, well-documented, and entirely capable of producing the subjective improvements that satisfied customers report in online reviews. Without controlled conditions, patients cannot reliably distinguish between pharmacological CBD effect and expectation-driven improvement.
Even the more rigorous CBD studies have methodological limitations: small sample sizes, short follow-up periods, heterogeneous patient populations, and variable dosing protocols. The leap from ‘CBD showed promise in a 72-person anxiety study’ to ‘these gummies will help your anxiety’ is a marketing leap, not a scientific one. Patients deserve to understand that distinction before spending money on a product with no regulatory accountability for its label claims.
Regulatory & Legal Analysis
The regulatory vacuum surrounding hemp-derived CBD ingestibles in Massachusetts in 2026 represents a genuine consumer protection failure. The FDA’s years-long delay in establishing a clear regulatory framework for CBD as a dietary supplement has left state regulators in an awkward position: hemp CBD products are legal to sell, widely available, and actively marketed for health conditions, yet they are not subject to the same pre-market safety review, manufacturing standards, or labeling accuracy requirements applied to pharmaceutical drugs or even conventional dietary supplements under DSHEA.
The CCC’s 935 CMR 501 framework, by contrast, is one of the most comprehensive cannabis regulatory structures in the country-mandating potency testing, contaminant screening, child-resistant packaging, accurate labeling, and seed-to-sale tracking. The irony is that a patient buying a $15 bag of Planta gummies at a convenience store has fewer consumer protections than a patient purchasing a $40 CBD tincture at a licensed Massachusetts dispensary.
Municipal zoning restrictions and host community agreement requirements have also created geographic disparities in dispensary access across Massachusetts, meaning that patients in certain communities face longer travel distances to access the regulated medical market. This practical barrier drives some patients toward OTC alternatives not out of preference but out of necessity-a policy gap that warrants attention from the CCC and the legislature.
Equity program access within the medical cannabis system also remains uneven. Low-income patients who would benefit most from the tax exemption and clinical oversight of the medical market often face barriers to certification-cost of consultation, lack of transportation, digital literacy gaps in the MassCIP portal-that effectively funnel them toward the unregulated OTC market. Addressing these structural inequities is as important as any pharmacological guidance.
Comparative State & Historical Context
Massachusetts legalized medical cannabis via Ballot Question 3 in November 2012, establishing one of the earliest and ultimately most patient-flexible medical cannabis frameworks in the Northeast. The subsequent evolution of 935 CMR 501 through multiple regulatory revision cycles has produced a system that, by 2026, offers physician discretion for qualifying conditions, same-day digital certification, and a tax exemption structure that meaningfully rewards patients who engage the medical system rather than the OTC market. The parallel rise of the hemp CBD market-accelerated by the 2018 federal Farm Bill-created a consumer landscape that the 2012 ballot architects could not have anticipated: millions of patients accessing cannabinoids outside any medical framework whatsoever.
States with more restrictive medical cannabis programs-those limiting qualifying conditions to a narrow statutory list without physician discretion-have paradoxically driven more patients toward the unregulated OTC CBD market, because the medical pathway is inaccessible for their conditions. Massachusetts’s broad ‘debilitating condition’ standard, interpreted generously by certifying physicians, means that most patients who would benefit from supervised CBD access can qualify for the medical program. That flexibility is a genuine policy achievement worth preserving and expanding.
Dispensary Realities & Budget
For a Massachusetts patient currently spending $50-$80 monthly on Planta or similar OTC CBD gummies, the financial math of medical cannabis certification is straightforward. A one-time or annual certification consultation fee, combined with the 17-20% tax exemption on all subsequent dispensary purchases, typically produces net savings within two to three months. A patient spending $60 monthly on dispensary CBD saves $10-$12 per transaction-$120-$144 annually-while gaining access to products with verified potency and physician oversight.
The practical dispensary experience for medical patients in Massachusetts is also meaningfully different from the adult-use retail experience. Medical menus often include higher-potency formulations, dedicated patient service windows with shorter wait times, and staff trained to discuss therapeutic applications rather than recreational preferences. For a patient seeking a specific CBD:THC ratio or a particular terpene profile for sleep versus daytime anxiety management, the medical dispensary environment is substantially more useful than a retail wellness store.
One practical caution: not all Massachusetts dispensaries carry the same CBD product selection, and availability of high-CBD, low-THC formulations can vary by location and season. Calling ahead, reviewing online menus, and asking your certifying physician for specific product recommendations by category-rather than brand-will consistently produce better outcomes than walking in and relying on budtender suggestions alone.
Federal Rescheduling & Research
The ongoing federal cannabis rescheduling process-moving cannabis from Schedule I toward Schedule III under the Controlled Substances Act-carries significant implications for the CBD gummy market and for medical cannabis research in 2026. Schedule III status would not legalize cannabis federally, but it would remove the most significant barriers to DEA-licensed clinical research, potentially enabling the large-scale randomized controlled trials that CBD’s evidence base currently lacks. It would also create pressure on the FDA to finally establish a clear regulatory pathway for CBD as a dietary supplement or functional food ingredient-a rulemaking process that has been anticipated for years and would fundamentally reshape the OTC CBD market’s accountability structure. Simultaneously, research into minor cannabinoids-CBG (cannabigerol) for its potential anti-inflammatory and neuroprotective properties, CBN (cannabinol) for sleep, and THCV for appetite modulation-is expanding rapidly, suggesting that the next generation of therapeutic cannabis formulations will move well beyond simple CBD isolate gummies toward precision multi-cannabinoid protocols tailored to individual endocannabinoid system profiles.
Common Myths & Misconceptions
💬 Join the Conversation
Have questions about qualifying for a medical marijuana card in Massachusetts? Ask Dr. Caplan →
Want to connect with other patients and discuss local dispensary options? Join the CED Clinic patient community forum →
Frequently Asked Questions
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
